| Name | Title | Contact Details |
|---|
TCR² Therapeutics Inc. is a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer. TCR²`s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while exhibiting lower levels of cytokine release.
QIAGEN is a German provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research.
Critical Path Services is a Garnet Valley, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AAI Pharmaceutical is a Wilmington, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Copan Diagnostics is a Murrieta, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.